These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 25264586)

  • 1. Application of urine proteomics for biomarker discovery in drug-induced liver injury.
    van Swelm RP; Kramers C; Masereeuw R; Russel FG
    Crit Rev Toxicol; 2014 Nov; 44(10):823-41. PubMed ID: 25264586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients.
    van Swelm RP; Laarakkers CM; Kooijmans-Otero M; de Jong EM; Masereeuw R; Russel FG
    Toxicol Lett; 2013 Aug; 221(3):219-24. PubMed ID: 23830989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolomic approaches in the discovery of potential urinary biomarkers of drug-induced liver injury (DILI).
    Araújo AM; Carvalho M; Carvalho F; Bastos ML; Guedes de Pinho P
    Crit Rev Toxicol; 2017 Sep; 47(8):633-649. PubMed ID: 28436314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel translational urinary biomarkers for acetaminophen-induced acute liver injury using proteomic profiling in mice.
    van Swelm RP; Laarakkers CM; van der Kuur EC; Morava-Kozicz E; Wevers RA; Augustijn KD; Touw DJ; Sandel MH; Masereeuw R; Russel FG
    PLoS One; 2012; 7(11):e49524. PubMed ID: 23166697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers for the diagnosis and management of drug-induced liver injury.
    Watkins PB
    Semin Liver Dis; 2009 Nov; 29(4):393-9. PubMed ID: 19826973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latest advances in predicting DILI in human subjects: focus on biomarkers.
    Hawkins MT; Lewis JH
    Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1521-30. PubMed ID: 22998122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of a discovery to targeted LC-MS proteomics approach to identify deregulated proteins associated with idiosyncratic liver toxicity in a rat model of LPS/diclofenac co-administration.
    Ramm S; Morissey B; Hernandez B; Rooney C; Pennington SR; Mally A
    Toxicology; 2015 May; 331():100-11. PubMed ID: 25772430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Progress in the biomarker discovery for drug-induced liver injury].
    He LY; Guo YX; Li C; Deng Y; Zhang QZ; Peng WX
    Yao Xue Xue Bao; 2015 Aug; 50(8):959-65. PubMed ID: 26668994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for drug-induced liver injury.
    Shi Q; Hong H; Senior J; Tong W
    Expert Rev Gastroenterol Hepatol; 2010 Apr; 4(2):225-34. PubMed ID: 20350268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?
    Teschke R; Schulze J; Eickhoff A; Danan G
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28398242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic profiling in incubation medium of mouse, rat and human precision-cut liver slices for biomarker detection regarding acute drug-induced liver injury.
    van Swelm RP; Hadi M; Laarakkers CM; Masereeuw R; Groothuis GM; Russel FG
    J Appl Toxicol; 2014 Sep; 34(9):993-1001. PubMed ID: 24038040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced liver injury and drug development: industry perspective.
    Regev A
    Semin Liver Dis; 2014 May; 34(2):227-39. PubMed ID: 24879986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Establishment of animal models of drug-induced liver injury and analysis of possible mechanisms].
    Oda S; Yokoi T
    Yakugaku Zasshi; 2015; 135(4):579-88. PubMed ID: 25832838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting idiosyncratic drug-induced liver injury: some recent advances.
    Chen M; Borlak J; Tong W
    Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):721-3. PubMed ID: 24857265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond.
    Lewis JH
    Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2173-89.e8. PubMed ID: 26116527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hopes and challenges in using miRNAs as translational biomarkers for drug-induced liver injury.
    Shi Q; Yang X; Mendrick DL
    Biomark Med; 2013 Apr; 7(2):307-15. PubMed ID: 23547824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers of drug-induced liver injury: a mechanistic perspective through acetaminophen hepatotoxicity.
    Umbaugh DS; Jaeschke H
    Expert Rev Gastroenterol Hepatol; 2021 Apr; 15(4):363-375. PubMed ID: 33242385
    [No Abstract]   [Full Text] [Related]  

  • 18. Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
    Eun JW; Bae HJ; Shen Q; Park SJ; Kim HS; Shin WC; Yang HD; Jin CY; You JS; Kang HJ; Kim H; Ahn YM; Park WS; Lee JY; Nam SW
    J Appl Toxicol; 2015 Feb; 35(2):152-64. PubMed ID: 25231249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Models of Idiosyncratic Drug-Induced Liver Injury.
    Yokoi T; Oda S
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():247-268. PubMed ID: 32976738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unraveling cellular pathways contributing to drug-induced liver injury by dynamical modeling.
    Kuijper IA; Yang H; Van De Water B; Beltman JB
    Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):5-17. PubMed ID: 27609146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.